These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22687735)

  • 1. [Quantitative evaluation method of the informational value of initial symptoms based on Bayesian theory].
    Ohshima S; Ieda M; Yamamoto M; Kobayashi D
    Yakugaku Zasshi; 2012; 132(6):763-8. PubMed ID: 22687735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study on the Increased Probability of Detecting Adverse Drug Reactions Based on Bayes' Theorem: Evaluation of the Usefulness of Information on the Onset Timing of Adverse Drug Reactions.
    Oshima S; Enjuji T; Negishi A; Akimoto H; Ohara K; Okita M; Numajiri S; Inoue N; Ohshima S; Terao A; Kobayashi D
    Biol Pharm Bull; 2017 Sep; 40(9):1389-1398. PubMed ID: 28579595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative evaluation of initial symptoms as predictors to detect adverse drug reactions using Bayes' theory: expansion and evaluation of drug-adverse drug reaction-initial symptom combinations using adverse event reporting system database.
    Kobayashi D; Hosaka S; Inoue E; Ohshima K; Kutsuma N; Oshima S; Okuno Y
    Biol Pharm Bull; 2013; 36(12):1891-901. PubMed ID: 24292049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of cross-hepatotoxicity between voriconazole and posaconazole.
    Foo H; Gottlieb T
    Clin Infect Dis; 2007 Sep; 45(6):803-5. PubMed ID: 17712772
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
    Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
    Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole: a new triazole antifungal agent.
    Johnson LB; Kauffman CA
    Clin Infect Dis; 2003 Mar; 36(5):630-7. PubMed ID: 12594645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole hepatotoxicity in severe liver dysfunction.
    Solís-Muñoz P; López JC; Bernal W; Willars C; Verma A; Heneghan MA; Wendon J; Auzinger G
    J Infect; 2013 Jan; 66(1):80-6. PubMed ID: 23041040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole: serious adverse effects and interactions.
    Prescrire Int; 2007 Feb; 16(87):18. PubMed ID: 17326278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database.
    Eiden C; Peyrière H; Cociglio M; Djezzar S; Hansel S; Blayac JP; Hillaire-Buys D;
    Ann Pharmacother; 2007 May; 41(5):755-63. PubMed ID: 17456542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of periostitis secondary to voriconazole therapy in a heart transplant recipient.
    Wise SM; Wilson MA
    Clin Nucl Med; 2011 Mar; 36(3):242-4. PubMed ID: 21285691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens.
    Burhenne J; Haefeli WE; Hess M; Scope A
    J Avian Med Surg; 2008 Sep; 22(3):199-207. PubMed ID: 19014092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse reactions to voriconazole.
    Boyd AE; Modi S; Howard SJ; Moore CB; Keevil BG; Denning DW
    Clin Infect Dis; 2004 Oct; 39(8):1241-4. PubMed ID: 15486850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole-induced photosensitivity.
    Malani AN; Aronoff DM
    Clin Med Res; 2008 Sep; 6(2):83-5. PubMed ID: 18801950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities.
    Tan K; Brayshaw N; Tomaszewski K; Troke P; Wood N
    J Clin Pharmacol; 2006 Feb; 46(2):235-43. PubMed ID: 16432276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of voriconazole hepatotoxicity in a lung transplant patient.
    Belaiche S; Roustit M; Bedouch P; Quetant S; Saint-Raymond C; Pison C
    Transpl Infect Dis; 2011 Jun; 13(3):309-11. PubMed ID: 21176020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Porphyria cutanea tarda revealed by voriconazole].
    Hickman G; Duval A; Picard C; Petit A
    Ann Dermatol Venereol; 2010 Jan; 137(1):36-9. PubMed ID: 20110066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
    Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH
    J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Painful peripheral neuropathy associated with voriconazole use.
    Tsiodras S; Zafiropoulou R; Kanta E; Demponeras C; Karandreas N; Manesis EK
    Arch Neurol; 2005 Jan; 62(1):144-6. PubMed ID: 15642862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.